Rock Creek Pharmaceuticals Announces Presentation of Four Anatabine Projects at Neuroscience 2014

SARASOTA, Fla., Oct. 23, 2014 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that abstracts outlining four separate preclinical studies evaluating anatabine, the primary constituent in the Company's lead investigational compound anatabine citrate, have been accepted for poster and nano symposium presentations at the upcoming annual meeting of the Society for Neuroscience, taking place November 15-19 in Washington, DC.  This meeting is the premier event in the field, typically attracting approximately 30,000 attendees, with 15,000 scientific presentations and nearly 600 presenting companies.

The studies were independently conducted by the Roskamp Institute, a not-for-profit research organization devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The studies were funded by either the Roskamp Foundation or by awards through the Congressionally Directed Medical Research Program. 

Michael J. Mullan, MBBS (MD), PhD, Rock Creek Pharmaceuticals' Chairman and CEO, commented, "The data from the accepted abstracts demonstrates the continued application of anatabine for beneficial effects in preclinical mouse models of human diseases."

A list of the abstracts and timing of the presentations is provided below:

About Anatabine Citrate:

Rock Creek Pharmaceuticals' anatabine citrate is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company has sponsored extensive pre-clinical in vitro and in vivo studies resulting in peer reviewed and scientific journal articles, covering inflammatory models of Multiple Sclerosis, Alzheimer's Disease, and Auto-Immune Thyroiditis. In addition, the Company's compilation of human exposure, safety and tolerability data, provides important insights for future clinical pathway progression.

About Rock Creek Pharmaceuticals:

Rock Creek Pharmaceuticals, Inc. is an emerging drug development company focused on the discovery, development and commercialization of new drugs, formulations and compounds that provide therapies for chronic inflammatory disease, neurologic disorders and behavioral health.

For more information, visit: http://www.rockcreekpharma.com

About the Roskamp Institute:

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer's disease. The Institute is located in Sarasota, Florida, and operates a memory clinic onsite.

For more information, visit: http://www.rfdn.org

CONTACT:

Ted Jenkins
Vice President, Corporate Strategy, Development, Investor Relations
Rock Creek Pharmaceuticals 
2040 Whitfield Avenue, Suite 300
Sarasota, FL  34243
Direct: 941-251-0488
[email protected]

Stephanie Carrington/ Bo Park 
Investors/Media 
Integrated Corporate Relations, Inc. (ICR): Redefining Strategic Communications 
685 Third Avenue, 2nd Floor,  
New York, NY 10017 
(646) 277-1282/(646) 277-1222 
[email protected] 
[email protected] 

Forward Looking Statements

Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and approval of anti-inflammatory drug candidates, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices and the outcome of the ongoing investigations as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2013 filed on March 17, 2014 and our latest 10-Q Report filed on August 11, 2014. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.

Logo - http://photos.prnewswire.com/prnh/20141023/153937LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rock-creek-pharmaceuticals-announces-presentation-of-four-anatabine-projects-at-neuroscience-2014-788799630.html

SOURCE Rock Creek Pharmaceuticals, Inc.

Related Links

http://www.rockcreekpharma.com